How Much Does Mounjaro Cost in Ohio in 2026?

Mounjaro Retail Pricing in Ohio

Mounjaro's wholesale acquisition cost from Eli Lilly sets the baseline at $1,023 per month for all dose strengths, and Ohio retail pharmacies generally pass that figure through as the cash-pay price [1]. Unlike older diabetes medications such as metformin, which costs pennies per tablet, tirzepatide has no generic equivalent. The FDA approved tirzepatide (brand name Mounjaro) in May 2022 for type 2 diabetes as an adjunct to diet and exercise [2].

Pricing does not change by dose. Whether a patient fills the starter 2.5 mg pen or the maximum 15 mg pen, the monthly cost remains the same at list price. Ohio pharmacies including major chains like CVS, Walgreens, and Kroger Pharmacy all reflect this manufacturer-set figure. Patients paying entirely out of pocket should expect to spend approximately $12,276 annually at retail price [1].

The SURPASS clinical trial program demonstrated tirzepatide's efficacy across doses. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline versus 1.86% with semaglutide 1 mg at 40 weeks [3]. That level of glycemic control explains why demand has remained high despite the cost. Ohio patients seeking the drug for weight loss specifically should know that Eli Lilly markets tirzepatide under a separate brand, Zepbound, for chronic weight management, approved by the FDA in November 2023 [4].

Ohio Medicaid Coverage for Mounjaro

Ohio Medicaid covers Mounjaro for type 2 diabetes, but does not extend coverage to off-label weight loss use. This distinction matters. A patient with a documented T2D diagnosis and a prescriber who submits appropriate clinical documentation (typically an HbA1c of 7% or above, or failure on first-line therapy) can obtain Mounjaro through Ohio Medicaid managed care plans [5]. Patients seeking tirzepatide purely for obesity without a diabetes diagnosis will not qualify.

Prior authorization is standard. Ohio Medicaid managed care organizations (MCOs), including CareSource, Molina, Anthem, and UnitedHealthcare Community Plan, each maintain their own preferred drug lists. The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists (including dual GIP/GLP-1 agents) for patients with T2D who have established cardiovascular disease or high cardiovascular risk [6]. This guideline backing can support prior authorization requests.

For weight management coverage through Medicaid, the picture is different. The Treat and Reduce Obesity Act has been introduced at the federal level multiple times but has not passed, and Ohio Medicaid does not independently cover anti-obesity medications [7]. Patients in this situation should explore the alternative pricing pathways below.

Commercial Insurance Coverage in Ohio

Major commercial insurers in Ohio do cover Mounjaro, though formulary placement and cost-sharing vary by plan. Anthem Blue Cross Blue Shield, Medical Mutual of Ohio, and UnitedHealthcare each list tirzepatide on their formularies for type 2 diabetes, typically at a specialty or non-preferred brand tier [8]. Monthly copays through commercial insurance range from $25 to $150 depending on plan design and whether the patient applies the manufacturer savings card.

Step therapy requirements are common. Many Ohio plans require documented failure on or intolerance to metformin before approving tirzepatide [6]. Some plans also require prior trial of a GLP-1 receptor agonist such as semaglutide before covering the dual GIP/GLP-1 agent. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity supports GLP-1 and dual-incretin therapies as second-line agents when lifestyle intervention proves insufficient [9].

Patients with high-deductible health plans face the full $1,023 monthly cost until meeting their deductible. The Eli Lilly Savings Card can offset some of this expense, but it does not apply to deductible accumulation on all plan types.

The Eli Lilly Savings Card: How It Works in Ohio

Eli Lilly's Mounjaro Savings Card offers eligible commercially insured patients a copay as low as $25 per month, with a maximum benefit of $150 per prescription fill. The card is available to Ohio residents with commercial insurance who have a valid prescription [10]. It cannot be combined with government insurance programs including Medicaid, Medicare, or Tricare.

Eligibility requires that the patient's commercial plan covers Mounjaro. The card reduces the patient's out-of-pocket share after insurance adjudication, not the total drug cost. Patients whose insurance does not cover tirzepatide at all are not eligible for the savings card program. Lilly periodically adjusts savings card terms, and Ohio patients should verify current benefits at the manufacturer's website or through their prescribing provider.

One practical point: the savings card benefit resets annually and carries a maximum annual cap. Patients using the card should confirm remaining benefit with each fill to avoid unexpected costs mid-year.

Compounded Tirzepatide in Ohio

Compounded tirzepatide is available through licensed 503A compounding pharmacies in Ohio at approximately $249 per month. This represents a 76% reduction compared to brand-name Mounjaro. Ohio permits 503A compounding pharmacies to prepare patient-specific prescriptions when a prescriber writes an individual order [11].

The legal basis rests on FDA guidance. The FDA maintains a drug shortage list, and tirzepatide appeared on that list during 2023-2024, which expanded compounding eligibility under section 503A of the Federal Food, Drug, and Cosmetic Act [11]. The FDA has since signaled that tirzepatide shortage status is being reevaluated, and Ohio patients considering compounded versions should confirm current shortage designation with their pharmacy.

Quality matters. The FDA does not verify compounded drugs for safety, efficacy, or manufacturing quality the way it does for FDA-approved products [12]. Ohio Board of Pharmacy regulations require 503A pharmacies to comply with United States Pharmacopeia (USP) standards for sterile compounding (USP chapter 797) [13]. Patients should verify that their compounding pharmacy holds current Ohio Board of Pharmacy licensure and follows USP 797 protocols.

Compounded tirzepatide is typically dispensed as a multi-dose vial requiring the patient to draw and inject a measured dose, rather than the pre-filled auto-injector pen used for brand Mounjaro. This difference in delivery device means patients need instruction on proper reconstitution and injection technique.

Telehealth Access to Mounjaro in Ohio

Ohio permits telehealth prescribing of Mounjaro, and multiple telehealth platforms serve Ohio residents. State law allows synchronous audio-video visits to establish a prescriber-patient relationship for controlled and non-controlled medications [14]. Tirzepatide is not a controlled substance, so prescribing via telehealth encounters no DEA scheduling barriers.

Telehealth visits typically cost $50 to $150 for an initial consultation, with follow-up visits ranging from $30 to $75. Some platforms bundle the visit cost with the medication price, particularly those partnering with compounding pharmacies. Ohio patients using telehealth should confirm that their provider is licensed in Ohio and that the pharmacy filling the prescription (whether retail or compounding) is Ohio-licensed or holds a non-resident pharmacy license recognized by the Ohio Board of Pharmacy [13].

The American Telemedicine Association has endorsed telehealth-based prescribing for chronic disease management, including diabetes and obesity [15]. For Mounjaro specifically, telehealth works well because follow-up visits primarily involve dose titration adjustments and lab review rather than physical examination.

Comparing Ohio Mounjaro Costs to Alternatives

Ohio patients weighing tirzepatide against other GLP-1 receptor agonists should consider both clinical efficacy and pricing. Semaglutide (Ozempic for T2D, Wegovy for weight management) carries a list price of approximately $936 per month [16]. Liraglutide (Saxenda) costs roughly $1,349 per month at list price. Compounded semaglutide in Ohio typically runs $150 to $300 per month through 503A pharmacies.

Head-to-head data favor tirzepatide. SURPASS-2 showed tirzepatide 15 mg achieved a 2.58% HbA1c reduction versus 1.86% for semaglutide 1 mg (P<0.001) [3]. For weight loss, the SURMOUNT-1 trial (N=2,539) demonstrated 22.5% mean body weight reduction with tirzepatide 15 mg at 72 weeks versus 2.4% with placebo [17]. These results exceed what has been reported for semaglutide 2.4 mg in the STEP-1 trial (N=1,961), which showed 14.9% mean weight loss at 68 weeks [18].

Dual-incretin agonism (GIP plus GLP-1) may explain tirzepatide's superior efficacy. GIP receptor activation appears to enhance insulin secretion and may independently affect adipose tissue metabolism [19]. This pharmacological distinction, not just dose optimization, drives the clinical difference.

For Ohio patients focused on cost-effectiveness, compounded tirzepatide at $249 per month offers the clinical profile of a dual-incretin agent at a price point below most brand GLP-1 options.

Dose Titration and Long-Term Cost Planning

Mounjaro dosing starts at 2.5 mg weekly for four weeks, then increases to 5 mg [2]. The prescriber may titrate further in 2.5 mg increments every four weeks to a maximum of 15 mg weekly, based on glycemic response and tolerability. Because the monthly price stays constant across doses, titration does not change the cost at retail.

Long-term planning should account for treatment duration. Both the ADA Standards of Care and the Endocrine Society guideline indicate that GLP-1 and dual-incretin therapies require ongoing use to maintain glycemic and weight benefits [6][9]. Weight regain after discontinuation has been documented. In the SURMOUNT-1 open-label extension, participants who stopped tirzepatide regained approximately two-thirds of lost weight within one year [20].

For an Ohio patient on brand Mounjaro at list price, annual cost reaches $12,276. Over five years, that totals $61,380. Compounded tirzepatide at $249 monthly reduces the five-year figure to $14,940. These numbers make the choice of access pathway a significant long-term financial decision.

Ohio-Specific Discount and Assistance Programs

Beyond the Lilly Savings Card, Ohio patients can explore several additional avenues. Ohio's Best Rx program, administered through the Ohio Department of Medicaid, provides prescription discount cards to uninsured and underinsured residents [5]. While savings vary by drug, the card can be used at participating Ohio pharmacies for brand-name medications including Mounjaro.

Patient assistance programs (PAPs) from Eli Lilly may provide Mounjaro at no cost to patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level) and lack prescription drug coverage [10]. Applications require documentation of income and insurance status.

340B-eligible health centers in Ohio, including federally qualified health centers (FQHCs), purchase outpatient drugs at significantly reduced prices under the 340B Drug Pricing Program administered by HRSA [21]. Ohio patients receiving care at an FQHC may access Mounjaro at 340B pricing, which can reduce costs substantially compared to retail.